Expression of JWA and XRCC1 As Prognostic Markers for Gastric Cancer Recurrence

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2021 Jan 11

PMID 33425112

Citations 4

Authors

Weimin Wang

Jingjing Yang

Yan Yu

Jianliang Deng

Hui Zhang

Qiang Yao

Yongyan Fan

Yan Zhou

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is one of the common gastrointestinal tumors. Tumor recurrence leads to a high death rate of gastric cancer. It is very important to find markers to effectively predict gastric cancer recurrence. We constructed a gastric cancer tissue microarray containing 89 tumors and corresponding normal tissues to explore the relationship between some proteins' expression and gastric cancer recurrence. The expression of JWA, Cullin1, p53, XRCC1, CHIP, FAK, MMP-2, MDM2 and p21 was determined on the microarray by immunohistochemistry. The relationship between the expression of these proteins and gastric cancer recurrence was analyzed. Tumor diameter, lymph node metastasis, and TNM stage were closely related with gastric cancer recurrence by Fisher's exact test (P<0.05). We used the univariate Cox regression analysis to find that JWA, XRCC1 were related to gastric cancer recurrence (P<0.05); Lymph node metastasis and TNM stage were closely related to gastric cancer recurrence (P<0.05). Multivariate Cox regression analysis revealed that XRCC1 or lymph node metastasis were independent risk factors of gastric cancer recurrence (P<0.05). Kaplan-Meier survival curve assay indicated that patients with low JWA or XRCC1 expression in gastric cancer had significantly shorter DFS than those with high-expressed proteins (P<0.05). JWA or XRCC1 may be effective markers to predict gastric cancer recurrence.

Citing Articles

Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia.

Bao X, Chen Y, Chang J, Du J, Yang C, Wu Y BMC Cancer. 2025; 25(1):273.

PMID: 39955536 PMC: 11830216. DOI: 10.1186/s12885-025-13658-3.

Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.

Zhang J, Zhang Q, Zhao B, Shi G Abdom Radiol (NY). 2024; 49(11):3780-3796.

PMID: 38796795 PMC: 11519172. DOI: 10.1007/s00261-024-04331-7.

Upregulation of XRCC1 DNA Repair Gene, Interleukin-8, and Bcl-2 Antiapoptotic Gene Levels in Kurdish Patients with Gastric Adenocarcinoma.

Auni Kamal D, Fisal Shakir Agha N, Housein Z Arch Razi Inst. 2023; 78(3):989-995.

PMID: 38028855 PMC: 10657924. DOI: 10.22092/ARI.2022.360240.2567.

ARL6IP5 Ameliorates α-Synuclein Burden by Inducing Autophagy via Preventing Ubiquitination and Degradation of ATG12.

Siddique I, Kamble K, Gupta S, Solanki K, Bhola S, Ahsan N Int J Mol Sci. 2023; 24(13).

PMID: 37445677 PMC: 10341401. DOI: 10.3390/ijms241310499.

Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery.

Ding K, Liu X, Wang L, Zou L, Jiang X, Li A Cancers (Basel). 2022; 14(19).

PMID: 36230577 PMC: 9564207. DOI: 10.3390/cancers14194655.

References

Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y . Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 2012; 18(10):2987-96. DOI: 10.1158/1078-0432.CCR-11-2863. View

Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y . Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2010; 42(3):375-83. DOI: 10.1016/j.humpath.2010.09.003. View

Wu J, Liu X, Cai H, Wang Y . Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression. World J Surg Oncol. 2014; 12:40. PMC: 3996074. DOI: 10.1186/1477-7819-12-40. View

Ajani J, Bentrem D, Besh S, DAmico T, Das P, Denlinger C . Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013; 11(5):531-46. DOI: 10.6004/jnccn.2013.0070. View

Schwarz R . Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002; 9(4):394-400. DOI: 10.1007/BF02573875. View

Isozaki H, Okajima K, Fujii K . Histological evaluation of lymph node metastasis on serial sectioning in gastric cancer with radical lymphadenectomy. Hepatogastroenterology. 1997; 44(16):1133-6. View

Lim J, Yoon S, Hong S, Kim J, Choi S, Cho J . Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World J Gastroenterol. 2012; 18(39):5581-8. PMC: 3482645. DOI: 10.3748/wjg.v18.i39.5581. View

Kim J, Jang Y, Park S, Park S, Mok Y . Benefit of post-operative surveillance for recurrence after curative resection for gastric cancer. J Gastrointest Surg. 2010; 14(6):969-76. DOI: 10.1007/s11605-010-1200-4. View

Bao G, Qiao Q, Zhao H, He X . Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol. 2010; 8:52. PMC: 2909949. DOI: 10.1186/1477-7819-8-52. View

10.

Chu D, Zhu S, Li J, Ji G, Wang W, Wu G . CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One. 2014; 9(6):e101027. PMC: 4076217. DOI: 10.1371/journal.pone.0101027. View

11.

Zhang X, Huang C, Lu H, Wu X, Wang C, Guang G . Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol. 2004; 10(23):3405-8. PMC: 4576218. DOI: 10.3748/wjg.v10.i23.3405. View

12.

Camilo V, Barros R, Celestino R, Castro P, Vieira J, Teixeira M . Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer. 2014; 14:753. PMC: 4210532. DOI: 10.1186/1471-2407-14-753. View

13.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

14.

Nitti D, Marchet A, Mammano E, Ambrosi A, Belluco C, Mencarelli R . Extended lymphadenectomy (D2) in patients with early gastric cancer. Eur J Surg Oncol. 2005; 31(8):875-81. DOI: 10.1016/j.ejso.2005.05.013. View

15.

Noh S, Park S, Yang H, Chung H, Chung I, Kim S . Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(12):1389-96. DOI: 10.1016/S1470-2045(14)70473-5. View

16.

Wu C, Lo S, Shen K, Hsieh M, Chen J, Chiang J . Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003; 27(2):153-8. DOI: 10.1007/s00268-002-6279-7. View

17.

Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y, Ono H . Surgical outcome in patients with gastric adenocarcinoma in the upper third of the stomach. Surgery. 2005; 137(2):165-71. DOI: 10.1016/j.surg.2004.06.005. View

18.

Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y . High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol. 2013; 48(9):1034-44. DOI: 10.1007/s00535-012-0724-7. View

19.

Lee S, Ryu K, Nam B, Lee J, Choi I, Kook M . Prognostic significance of intraoperatively estimated surgical stage in curatively resected gastric cancer patients. J Am Coll Surg. 2009; 209(4):461-7. DOI: 10.1016/j.jamcollsurg.2009.06.001. View

20.

Liu X, Xiong H, Li J, He Y, Yuan X . Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol. 2013; 8:62. PMC: 3674969. DOI: 10.1186/1746-1596-8-62. View